Cellegy Pharmaceuticals is a specialty biopharmaceutical company engaged in the development and commercialization of prescription drugs with primary focus in the areas of gastroenterology, sexual dysfunction and women's health care. The Company is currently awaiting action by the FDA on marketing approval of Fortigel, its once-a-day gel product for the treatment of male hypogonadism. Commercial rights to Fortigel in North America have been licensed to PDI. Cellegy is also developing a second testosterone product, Tostrelle™ gel, for the treatment of female sexual dysfunction. Tostrelle is undergoing a Phase II/III clinical trial in the United States.
 

349 Oyster Point Blvd., Suite 200 South San Francisco, CA 94080 
Phone: (650) 616-2200 Fax: (650) 616-2222